Replicating Risk Genes in Bipolar Disorder
A new genetic study in Biological Psychiatry
Philadelphia, PA, October 15, 2012 – One of the biggest challenges in psychiatric genetics has been to replicate findings across large studies.
Scientists at King’s College London, Institute of Psychiatry have now performed one of the largest ever genetic replication studies of bipolar affective disorder, with 28,000 subjects recruited from 36 different research centers. Their findings provide compelling evidence that the chromosome 3p21.1 locus contains a common genetic risk for bipolar disorder, the PBRM1 gene.
The locus at 3p21.1 has also been previously associated with depression and schizophrenia. Using a separate dataset of over 34,000 subjects, they did not confirm association of this same variant with schizophrenia.
Thus, they replicated the association of the marker with bipolar disorder, but not with schizophrenia. This is an interesting finding, in that it distinguishes the heritable risk for bipolar disorder and schizophrenia. It contrasts with the majority of studies that have found that schizophrenia risk genes also contribute to the risk for bipolar disorder.
“This study adds to the recent rapid progress in identifying genes for mental illness. The last few years have seen the identification of about two dozen genetic loci for bipolar disorder and schizophrenia,” commented first author Evangelos Vassos. “About half of these are shared between these two disorders, indicating they share some, but not all, genetic causes.”
Due to the conflicting results, it is clear that more work is needed to determine the role this locus plays in psychosis, but the evidence seems solid that it is associated with bipolar disorder.
PBRM1, the gene implicated in this study, codes for a protein that is involved in chromatin remodeling or “epigenetics,” meaning that it influences the ability of a variety of environmental exposures to influence the expression of a range of genes. It has also been previously implicated in the risk for a form of renal cancer.
“There is growing interest in epigenetic mechanisms that might contribute to the development of bipolar disorder. The implication of a gene involved in chromatin remodeling in bipolar disorder risk adds fuel to this fire,” commented Dr. John Krystal, Editor ofBiological Psychiatry.
Vassos concluded that “future studies may be able to use this information to develop new treatments for these disorders.”
The article is “Replication Study and Meta-Analysis in European Samples Supports Association of the 3p21.1 Locus with Bipolar Disorder” by Evangelos Vassos, Stacy Steinberg, Sven Cichon, Gerome Breen, Engilbert Sigurdsson, Ole A. Andreassen, Srdjan Djurovic, Gunnar Morken, Maria Grigoroiu-Serbanescu, Carmen C. Diaconu, Piotr M. Czerski, Joanna Hauser, Gulja Babadjanova, Lilia I. Abramova, Thomas W. Mühleisen, Markus M. Nöthen, Marcella Rietschel, Peter McGuffin, David St. Clair, Omar Gustafsson, Ingrid Melle, Olli P.H. Pietiläinen, Mirella Ruggeri, Sarah Tosato, Thomas Werge, Roel A. Ophoff, GROUP Consortium, Dan Rujescu, Anders D. Børglum, Ole Mors, Preben B. Mortensen, Ditte Demontis, Mads V. Hollegaard, Ruud van Winkel, Gunter Kenis, Marc De Hert, János M. Réthelyi, István Bitter, I. Alex Rubino, Vera Golimbet, Lambertus A. Kiemeney, Leonard H. van den Berg, Barbara Franke, Erik G. Jönsson, Anne Farmer, Hreinn Stefansson, Kari Stefansson, and David A. Collier (doi: 10.1016/j.biopsych.2012.02.040). The article appears in Biological Psychiatry, Volume 72 Issue 8 (October 15, 2012), published by Elsevier.
# # #
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Seil Collins at +44 (0) 207 848 5377 or email@example.com.
The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 129 Psychiatry titles and 16th out of 243 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2011 Impact Factor score for Biological Psychiatry is 8.283.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact
Rhiannon Bugno, Editorial Office
+1 214 648 0880